CNL and aCML should be considered as a single entity based on molecular profiles and outcomesGonzalo Carreño‐Tarragona, Nicholas C.P. Cross, José Carlos Martínez Ávila et al.|Blood Advances|2023Cited by 32
Optical genome mapping in myelofibrosis: enhancing prognostic accuracy through high-resolution genomic profilingEsperanza Such, Elvira Mora, Marta Garrote et al.|Blood Advances|2025Cited by 2